SENS

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
DeFalco Stephen PDirector --9.9k shares Grant / ExerciseMay 20, 2026 Disclosure amount unavailable9.9k shares -- $6.72
DeFalco Stephen PInsider --13.6k shares Grant / ExerciseMay 20, 2026 Disclosure amount unavailable13.6k shares -- $6.72
DeFalco Stephen PInsider --9.9k shares Grant / ExerciseMay 20, 2026 Disclosure amount unavailable9.9k shares -- $6.72
Fiorentino EdwardInsider --9.9k shares Grant / ExerciseMay 20, 2026 Disclosure amount unavailable9.9k shares -- $6.72
Fiorentino EdwardDirector --9.9k shares Grant / ExerciseMay 20, 2026 Disclosure amount unavailable9.9k shares -- $6.72
Fiorentino EdwardInsider --13.6k shares Grant / ExerciseMay 20, 2026 Disclosure amount unavailable13.6k shares -- $6.72

News

globenewswire.comReal-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systemsglobenewswire.comJun 6

seekingalpha.comSenseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcriptseekingalpha.comJun 6

globenewswire.comSenseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026globenewswire.comJun 1

marketbeat.comSenseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlightsmarketbeat.comMay 8

seekingalpha.comSenseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 8

Trade SENS

About Senseonics Holdings, Inc.

Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.

CEO: Timothy T. Goodnow
IPO Date: Dec 22, 2015

Market Data

Open: $7.20
High: $7.69
Low: $7.06
Volume: 777.6K
52W High: $12.58
52W Low: $4.79

Valuation

Market Cap: $310M
Enterprise Value: $324M

Financials

Free Cash Flow: $-60M
Revenue: $35M
Net Income: $-69M
Cash: $41M
Debt: $41M

Events

EarningsAug 6

EPS est. -0.61263